Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Challenges in conducting therapeutic trials in Wegener's granulomatosis

From: Wegener's granulomatosis: current and upcoming therapies

Rarity of Wegener's granulomatosis
Potential for active disease to be life threatening
Available treatment of established efficacy
Definition of outcome measures
Imprecise means of assessing active disease
Extended follow-up is necessary to fully assess relapse and to reach study endpoints